Serum Mesothelin and Megakaryocyte Potentiating Factor in Pancreatic and Biliary Cancers

Overview

Journal Clin Chem Lab Med

Specialties Biochemistry
Pathology

Date 2011 Dec 14

PMID 22149739

Citations 14

Authors

Elad Sharon

Jingli Zhang

Kevin Hollevoet

Seth M Steinberg

Ira Pastan

Masanori Onda

Jochen Gaedcke

B Michael Ghadimi

Thomas Ried

Raffit Hassan

Affiliations

Soon will be listed here.

Abstract

Background: Tumor mesothelin overexpression is present in different malignancies, including the majority of patients with pancreatic or biliary cancers. The objective of this study was to evaluate the use of shed serum mesothelin and megakaryocyte potentiating factor (MPF) concentrations as biomarkers for these cancers.

Methods: A total of 151 individuals, divided into five groups, were retrospectively analyzed: healthy donors (n=15), patients with benign non-pancreatic conditions (n=52), benign pancreatic conditions (n=33), biliary carcinoma (n=9), and pancreatic ductal adenocarcinoma (n=42). Mesothelin and MPF concentrations were measured in serum with the Mesomark™ and Human MPF ELISA, respectively.

Results: Mesothelin and MPF concentrations did not significantly differ among the five individual participant groups (p=0.34, p=0.33, respectively), nor did any other combination and pair-wise comparison of the participant groups demonstrated a significant difference in biomarker concentrations. In patients with pancreatic cancer, mesothelin or MPF concentrations were not associated with tumor stage (p=0.87, p=0.48, respectively) or differentiation grade (p=0.73, p=0.52, respectively).

Conclusions: Serum mesothelin and MPF concentrations, measured with standard available ELISAs, were not specific for benign or pancreatic disease. Both biomarkers were not elevated in patients with pancreatic or biliary cancers, and consequently do not appear to be useful biomarkers for these malignancies.

Citing Articles

Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients' Sera.

Duran A, Guerrero P, Ortiz M, Perez Del Campo D, Castro E, Garcia-Velasco A Biomedicines. 2022; 10(8).

PMID: 36009489 PMC: 9405996. DOI: 10.3390/biomedicines10081942.

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment.

Zhang X, Yu Y, Peer C, Landsman R, Skorupan N, Cao L Transl Oncol. 2022; 21:101440.

PMID: 35523008 PMC: 9079715. DOI: 10.1016/j.tranon.2022.101440.

Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?.

ONeill R, Stoita A World J Gastroenterol. 2021; 27(26):4045-4087.

PMID: 34326612 PMC: 8311531. DOI: 10.3748/wjg.v27.i26.4045.

From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma.

Montemagno C, Cassim S, Pouyssegur J, Broisat A, Pages G Int J Mol Sci. 2020; 21(11).

PMID: 32517181 PMC: 7312874. DOI: 10.3390/ijms21114067.

Tc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma.

Montemagno C, Cassim S, Trichanh D, Savary C, Pouyssegur J, Pages G Cancers (Basel). 2019; 11(10).

PMID: 31658755 PMC: 6827014. DOI: 10.3390/cancers11101531.

References

Creaney J, Francis R, Dick I, Musk A, Robinson B, Byrne M . Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res. 2010; 17(5):1181-9. DOI: 10.1158/1078-0432.CCR-10-1929. View

Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y . Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer. 2008; 62(1):45-54. DOI: 10.1016/j.lungcan.2008.02.012. View

Johnston F, Tan M, Tan Jr B, Porembka M, Brunt E, Linehan D . Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res. 2009; 15(21):6511-8. PMC: 2782601. DOI: 10.1158/1078-0432.CCR-09-0565. View

Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpre P, De Vuyst P . The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest. 2011; 141(2):477-484. DOI: 10.1378/chest.11-0129. View

Hassan R, Laszik Z, Lerner M, Raffeld M, Postier R, Brackett D . Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2006; 124(6):838-45. View

Hassan R, Bera T, Pastan I . Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004; 10(12 Pt 1):3937-42. DOI: 10.1158/1078-0432.CCR-03-0801. View

Beyer H, Geschwindt R, Glover C, Tran L, Hellstrom I, Hellstrom K . MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem. 2007; 53(4):666-72. DOI: 10.1373/clinchem.2006.079327. View

Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz R . Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001; 7(12):3862-8. View

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

10.

Hellstrom I, Raycraft J, Kanan S, Sardesai N, Verch T, Yang Y . Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev. 2006; 15(5):1014-20. DOI: 10.1158/1055-9965.EPI-05-0334. View

11.

Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquee L, De Vuyst P . Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol. 2011; 6(11):1930-7. DOI: 10.1097/JTO.0b013e3182272294. View

12.

Robinson B, Creaney J, Lake R, Nowak A, William Musk A, de Klerk N . Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003; 362(9396):1612-6. DOI: 10.1016/S0140-6736(03)14794-0. View

13.

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

14.

Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J . ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24(33):5313-27. DOI: 10.1200/JCO.2006.08.2644. View

15.

Payne S, Stebbing J, Wilson P, Slater S . Outcomes in unresectable and locally advanced resected cholangiocarcinoma. Expert Rev Anticancer Ther. 2011; 11(5):705-9. DOI: 10.1586/era.11.32. View

16.

Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K . Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas. 2011; 40(8):1276-82. DOI: 10.1097/MPA.0b013e318221bed8. View

17.

Szajda S, Waszkiewicz N, Chojnowska S, Zwierz K . Carbohydrate markers of pancreatic cancer. Biochem Soc Trans. 2011; 39(1):340-3. DOI: 10.1042/BST0390340. View

18.

Creaney J, van Bruggen I, Hof M, Segal A, Musk A, de Klerk N . Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest. 2007; 132(4):1239-46. DOI: 10.1378/chest.07-0013. View

19.

Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T . Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med. 2011; 49(10):1721-6. DOI: 10.1515/CCLM.2011.242. View

20.

Hassan R, Remaley A, Sampson M, Zhang J, Cox D, Pingpank J . Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006; 12(2):447-53. DOI: 10.1158/1078-0432.CCR-05-1477. View